LoadingLoadingLoadingNet selling: insiders sold $2.5M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full results8 funds hold a position and insiders have been net buying.
Buys/Adds (2)
AQR
$30.5M
added
Two Sigma
$22.5M
added
Sells/Trims (1)
Point72
$37.0M
trimmed
Top-trader positions in MMSI could not be loaded.
Hyperliquid positioning - not every stock is covered
Last report
Jul 30, 2026
Period ending
Jun 30, 2026
Earnings per share
$0.85 expected
Revenue
Financial statements: Alpha Vantage
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 30, 2026 | $1.09 / $0.85Alpha Vantage | +28.24% beat | $418.8M No estimate | Unavailable |
| Mar 31, 2026 | Apr 30, 2026 | $0.94 / $0.83Alpha Vantage | +13.25% beat | $381.9M No estimate | Unavailable |
| Dec 31, 2025 | Feb 24, 2026 | $1.04 / $0.95Alpha Vantage | +9.50% beat | $394.2M No estimate | Unavailable |
| Sep 30, 2025 | Oct 30, 2025 | $0.92 / $0.83Alpha Vantage | +10.84% beat | $384.3M No estimate | Unavailable |
| Jun 30, 2025 | Jul 30, 2025 | $1.01 / $0.85Alpha Vantage | +18.82% beat | $382.0M No estimate | Unavailable |
| Mar 31, 2025 | Apr 24, 2025 | $0.86 / $0.75Alpha Vantage | +14.67% beat | $354.3M No estimate | Unavailable |
| Dec 31, 2024 | Feb 25, 2025 | $0.93 / $0.83Alpha Vantage | +12.05% beat | $355.2M No estimate | Unavailable |
| Sep 30, 2024 | Oct 30, 2024 | $0.86 / $0.80Alpha Vantage | +7.50% beat | $339.8M No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $384.3M | $394.2M | $381.9M | $418.8M |
| Cost of what it sold | $197.7M | $198.7M | $197.1M | $203.7M |
| Gross profit | $186.5M | $195.4M | $184.8M | $215.2M |
| What it spent | ||||
| Research and development | $24.0M | $26.5M | $22.6M | $25.4M |
| Sales and admin | $119.8M | $114.8M | $118.2M | $129.2M |
| Total operating expenses | $143.8M | $141.4M | $140.8M | $154.6M |
| What was left | ||||
| Operating profit | $42.8M | $54.1M | $44.0M | $60.5M |
| Interest on debt | $6.8M | $6.4M | $6.5M | $12.1M |
| Profit before tax | $38.5M | $51.1M | $53.5M | $51.3M |
| Tax | $10.8M | $13.1M | $12.6M | $12.5M |
| Net profit | $27.8M | $38.0M | $41.0M | $38.8M |
| EBITDA | $79.5M | $91.8M | $93.4M | $97.4M |
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Medical Devices & Supplies - Cardiology, Neurology, Vascular Q2 Earnings: Merit Medical Systems (NASDAQ:MMSI) Simply the Best
BullishOct 15Price-Driven Insight from (MMSI) for Rule-Based Strategy
NeutralOct 13Merit Medical Systems (MMSI) Stock Looks Cheap Based On Cash Flow
BullishOct 10Cancer Stocks to Consider as Oncology Innovation Accelerates
Leans bullishOct 9Merit Medical Systems, Inc. (MMSI) Stock Forecasts
NeutralOct 9Merit Medical Systems Sets Oct. 29 Q3 Results Date | MMSI Stock News
NeutralOct 7Merit Medical Systems to Announce Third Quarter 2026 Results on October 29, 2026
NeutralOct 6Here's Why You Should Add Merit Medical Stock to Your Portfolio Now
BullishOct 6